---
title: 'Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy
  for Transplant-Eligible Newly Diagnosed Multiple Myeloma: Final Part 1 Analysis
  of the GMMG-HD7 Trial'
date: '2024-12-09'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39652594/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20241209184155&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: 'Previously, addition of isatuximab (Isa) to standard-of-care lenalidomide-bortezomib-dexamethasone
  (RVd) in transplant-eligible patients with newly diagnosed multiple myeloma in the
  GMMG-HD7 trial (ClinicalTrials.gov identifier: NCT03617731) resulted in a significant
  increase of minimal residual disease negativity (MRD-) rates after induction therapy.
  A total of 662 patients were randomly assigned to receive induction therapy with
  Isa-RVd (n = 331) or RVd (n = 329), followed by single or ...'
disable_comments: true
---
Previously, addition of isatuximab (Isa) to standard-of-care lenalidomide-bortezomib-dexamethasone (RVd) in transplant-eligible patients with newly diagnosed multiple myeloma in the GMMG-HD7 trial (ClinicalTrials.gov identifier: NCT03617731) resulted in a significant increase of minimal residual disease negativity (MRD-) rates after induction therapy. A total of 662 patients were randomly assigned to receive induction therapy with Isa-RVd (n = 331) or RVd (n = 329), followed by single or ...